

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	10	("6673829" "6562847" "6888001" "20050215559" "6525070" "6903115").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/28 14:46
L2	26871	(ohtake naya haga jitsuoka suga tokita kanatani).in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/28 14:50
L3	3	l2 and (heteroaryl\$ and saturated).ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/28 14:50

=> b reg

FILE 'REGISTRY' ENTERED AT 16:09:26 ON 22 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

DICTIONARY FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l30

L9 STR



VAR G1=C/N

REP G2=(0-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L11 51529 SEA FILE=REGISTRY SSS FUL L9

L12 STR




REP G2=(0-3) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L15 47061 SEA FILE=REGISTRY SUB=L11 SSS FUL L12
 L16 4468 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L15
 L19 STR




REP G2=(0-3) C
 NODE ATTRIBUTES:
 NSPEC IS RC AT 14
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY AT 3
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L21 491 SEA FILE=REGISTRY SUB=L16 SSS FUL L19
 L22 STR



REP G1=(0-1) O
 REP G2=(0-3) C
 REP G3=(0-1) AK
 REP G4=(0-1) N
 VAR G5=AK/CY
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY AT 3
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

```

L24          120 SEA FILE=REGISTRY SUB=L16 SSS FUL L22
L25          610 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L21 OR L24)
L27          STR

```



```

REP G1=(0-1) O
REP G2=(0-3) C
REP G3=(0-1) AK
REP G4=(0-1) N
NODE ATTRIBUTES:
NSPEC   IS RC      AT 18
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY AT 3
DEFAULT ELEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 14

```
STEREO ATTRIBUTES: NONE
L29      127 SEA FILE=REGISTRY SUB=L11 SSS FUL L27
L30      622 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L25 OR L29)
```

```

=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:09:49 ON 22 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d bib abs hitind fhitstr retable 151 tot
```

L51 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1279121 HCAPLUS
 DN 146:45523
 TI Preparation of piperidine derivatives as histamine H3 receptor antagonists
 or inverse agonists
 IN Ishikawa, Shiho; Sato, Nagaaki; Nagase, Tsuyoshi; Tokita, Shigeru
 ; Wada, Toshihiro; Takahashi, Hidekazu
 PA Banyu Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 302pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2006129826	A1	20061207	WO 2006-JP311155	20060529
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				
	KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				
	MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,				
	SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,				
	VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				
	GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM				
PRAI	2005JP-0157739	A	20050530		
	2006JP-0115778	A	20060419		
OS	MARPAT 146:45523				
GI					



AB The title compds. [I; R1 = each (un)substituted aryl, 5- to 6-membered heteroaryl containing 1-3 heteroatoms selected from N, S, and O, heteroarylalkyl, alkyl, or arylcarbonyl (wherein the heteroaryl group is optionally fused to Ph or pyridyl group); R2 = aryl, heteroaryl containing 1-3 heteroatoms selected from N, S, and O, cyano, lower alkyl, lower alkoxy, HO; or R1 and R2 together form an (un)substituted 5- to 6-membered aliphatic heterocyclyl containing 1-3 heteroatoms selected from N, S, and O optionally fused to a Ph or pyridyl group; R3 = (CH₂)_{m1}NR₄R₅, Q, Q1; R4, R5, R7, R8 = lower alkyl, halo-lower alkyl, cycloalkyl, halocycloalkyl; or NR₄R₅ or N R₇R₈ forms an (un)substituted 5- to 8-membered monocyclic ring or 6- to 8-membered bicyclic ring; m1 = an integer of 1-4; R8 = lower alkyl, cycloalkyl; m2 = an integer of 0-4; X1 = X2 = X3 = X4 = (un)substituted CH; at least one or two of X1-X4 = N and the rest = (un)substituted CH] or pharmaceutically acceptable salts thereof are prepared These compds. have

an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. They are useful for the prevention and/or treatment of obesity, diabetes, hormone secretion disorders, hyperlipidemia, gout, fatty liver, angina pectoris, hypertension, etc. Thus, a mixture of 8-(4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one, 5-bromo-2-methoxypyridine, potassium phosphate, CuI, and N,N'-dimethylethylenediamine in 1,4-dioxane was heated at 110° in a sealed tube with stirring to give 8-(4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl)-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one (II). II in vitro inhibited the binding of [3H]N- α -methylhistamine with IC50 of 0.09 nM. Number

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 27

IT. 13472-85-0P, 5-Bromo-2-methoxypyridine 94635-24-2P, 1-(4-Methoxyphenyl)piperidin-4-one 101803-06-9P, 5-Iodo-2-methoxypyrimidine 117607-13-3P, (2R)-2-Methylpyrrolidine hydrobromide 223684-72-8P, 1-Ethyl-1-methyl-4-oxopiperidinium chloride 259664-14-7P, 1-[4-(Benzyloxy)phenyl]piperidin-4-one 273217-89-3P **346665-40-5P**, tert-Butyl 4-[(5-nitropyridin-2-yl)oxy]piperidine-1-carboxylate 397277-96-2P, 4-[(1-Isopropylpiperidin-4-yl)oxy]aniline 398473-98-8P, 1-[3-(4-Iodophenoxy)propyl]piperidine 634904-81-7P, 8-(4-Methoxyphenyl)-1,4-dioxo-8-azaspiro[4.5]decane 862311-57-7P, 3-((2S)-2-Methylpyrrolidin-1-yl)propan-1-ol 862311-76-0P, 3-((3S)-3-Methylpiperidin-1-yl)propan-1-ol 862314-38-3P, 3-((2R)-2-Methylpyrrolidin-1-yl)propan-1-ol 870521-31-6P, 5-Bromo-2-isopropoxypyridine 870997-86-7P, (3S)-3-Methylpiperidine (R)-mandelate 899452-26-7P, 5-Bromo-2-(difluoromethoxy)pyridine 916344-14-4P, (3S)-1-(3-Bromopropyl)-3-methylpiperidine hydrobromide 916344-16-6P, (2S)-1-(3-Bromopropyl)-2-methylpyrrolidine hydrobromide 916344-17-7P, (2R)-1-(3-Bromopropyl)-2-methylpyrrolidine hydrobromide 916344-18-8P, 8-[4-(Benzyloxy)phenyl]-1,4-dioxo-8-azaspiro[4.5]decane 916344-21-3P, 4-(Aminomethyl)-1-[4-(benzyloxy)phenyl]piperidin-4-ol 916344-22-4P, 4-(Aminomethyl)-1-(4-methoxyphenyl)piperidin-4-ol 916344-23-5P, 4-(Aminomethyl)-1-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]piperidin-4-ol 916344-24-6P, 4-(Aminomethyl)-1-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]piperidin-4-ol **916344-26-8P**, 4-(Aminomethyl)-1-[6-[(1-cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-ol **916344-28-0P**, 4-(Aminomethyl)-1-[6-[(1-isopropylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-ol 916344-30-4P, 4-(Aminomethyl)-1-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]piperidin-4-ol 916344-32-6P, N-[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl-2-chloroacetamide 916344-34-8P, 2-Chloro-N-[[4-hydroxy-1-(4-methoxyphenyl)piperidin-4-yl]methyl]acetamide 916344-36-0P, 2-Chloro-N-[[1-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-4-hydroxypiperidin-4-yl]methyl]acetamide 916344-38-2P, 2-Chloro-N-[[4-hydroxy-1-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]piperidin-4-yl]methyl]acetamide **916344-39-3P**, 2-Chloro-N-[[1-[6-[(1-cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-hydroxypiperidin-4-yl]methyl]acetamide 916344-40-6P, 9-[4-(Benzyloxy)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-41-7P, 9-(4-Methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-42-8P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-44-0P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916344-46-2P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-47-3P, tert-Butyl 9-[4-(benzyloxy)phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-carboxylate 916344-49-5P, tert-Butyl 9-(4-hydroxyphenyl)-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-carboxylate 916344-51-9P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-53-1P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-55-3P, 9-[4-[3-(Pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-57-5P, 9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-59-7P, 9-[4-[3-((2R)-2-

Methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-61-1P, 8-(4-Methoxyphenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-63-3P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-64-4P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-65-5P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-66-6P, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-67-7P, 8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-68-8P, 8-(4-Hydroxyphenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-69-9P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-70-2P, 916344-71-3P, 2-[(1-Cyclobutylpiperidin-4-yl)oxy]-5-nitropyridine 916344-73-5P, 2-[(1-Isopropylpiperidin-4-yl)oxy]-5-nitropyridine 4-methylbenzenesulfonate 916344-74-6P, 5-Amino-2-[(1-cyclobutylpiperidin-4-yl)oxy]pyridine 916344-75-7P, 5-Amino-2-[(1-isopropylpiperidin-4-yl)oxy]pyridine 916344-76-8P, 1-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]piperidin-4-one 916344-77-9P, 1-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]piperidin-4-one 916344-78-0P, 1-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-one 916344-79-1P, 1-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-one 916344-80-4P, 1-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]piperidin-4-one 916344-81-5P, 1'-[4-(3-Chloropropoxy)phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one 916344-87-1P, 9-[4-(Benzyloxy)phenyl]-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-88-2P, 9-(4-Hydroxyphenyl)-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-89-3P, 9-[4-(Benzyloxy)phenyl]-4-(3-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-90-6P, 9-(4-Hydroxyphenyl)-4-(3-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-91-7P, 9-[4-(Benzyloxy)phenyl]-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-92-8P, 4-(4-Fluorophenyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-93-9P, 4-(6-Fluoropyridin-3-yl)-9-[4-(benzyloxy)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-94-0P, 916344-95-1P, 9-(4-Benzyloxyphenyl)-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-96-2P, 9-(4-Hydroxyphenyl)-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-97-3P, 9-[4-(Benzyloxy)phenyl]-4-(6-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-98-4P, 9-(4-Hydroxyphenyl)-4-(6-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-99-5P, 9-[4-(Benzyloxy)phenyl]-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-00-1P, 9-(4-Hydroxyphenyl)-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-01-2P, 9-[4-(Benzyloxy)phenyl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-02-3P, 916345-03-4P, 9-[4-(Benzyloxy)phenyl]-4-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-04-5P, 9-(4-Hydroxyphenyl)-4-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-05-6P, 9-[4-(Benzyloxy)phenyl]-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-06-7P, 9-(4-Hydroxyphenyl)-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-07-8P, 9-[4-(Benzyloxy)phenyl]-4-(1-ethylpropyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-08-9P, 4-(1-Ethylpropyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-09-0P, 9-[4-(Benzyloxy)phenyl]-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-10-3P, 9-(4-Hydroxyphenyl)-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-11-4P, 1-[4-(Benzyloxy)phenyl]-4-[(cyclopropylamino)methyl]piperidin-4-ol 916345-13-6P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloro-N-cyclopropylacetamide 916345-14-7P, 9-[4-(Benzyloxy)phenyl]-4-cyclopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-15-8P, 4-Cyclopropyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-16-9P, 1-[4-(Benzyloxy)phenyl]-4-[(cyclobutylamino)methyl]piperidin-4-ol 916345-17-0P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloro-N-cyclobutylacetamide 916345-18-1P, 9-(4-Benzyloxyphenyl)-4-cyclobutyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-19-2P, 916345-20-5P,

1-[4-(Benzyloxy)phenyl]-4-[(cyclopentylamino)methyl]piperidin-4-ol
 916345-21-6P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-
 2-chloro-N-cyclopentylacetamide 916345-22-7P, 9-[4-(Benzyloxy)phenyl]-4-
 cyclopentyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-23-8P,
 4-Cyclopentyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916345-24-9P, 1-[4-(Benzyloxy)phenyl]-4-[(cyclohexylamino)methyl]piperidin-
 4-ol 916345-25-0P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-
 yl]methyl]-2-chloro-N-cyclohexylacetamide 916345-26-1P,
 9-[4-(Benzyloxy)phenyl]-4-cyclohexyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-
 one 916345-27-2P, 4-Cyclohexyl-9-(4-hydroxyphenyl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916345-28-3P, 4-Benzyl-9-[4-
 (benzyloxy)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-29-4P,
 4-Benzyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916345-30-7P, 4-(3-Fluorophenyl)-9-(4-methoxyphenyl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916345-31-8P, 4-(3-Fluorophenyl)-9-(4-
 hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-32-9P,
 4-(2-Fluorophenyl)-9-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-
 one 916345-33-0P, 4-(2-Fluorophenyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916345-34-1P, 4-(2-Fluoropyridin-4-yl)-9-(4-
 methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-35-2P,
 4-(2-Fluoropyridin-4-yl)-9-(4-hydroxyphenyl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916345-36-3P, 4-Ethyl-9-(4-methoxyphenyl)-1-
 oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-37-4P, 4-Methyl-9-(4-
 methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-38-5P,
 8-(4-Methoxyphenyl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916345-39-6P, 8-(4-Hydroxyphenyl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-
 2-one 916345-40-9P, 8-[4-(3-Chloropropoxy)phenyl]-3-phenyl-1-oxa-3,8-
 diazaspiro[4.5]decan-2-one 916345-41-0P, 3-[4-(Benzyloxy)phenyl]-8-[4-[3-
 (piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916345-42-1P, 9-(4-Methoxyphenyl)-4-phenyl-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916345-43-2P, 9-(4-Hydroxyphenyl)-4-phenyl-
 1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-44-3P, tert-Butyl
 4-[4-(3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-
 yl)phenoxy]piperidine-1-carboxylate 916345-45-4P, 9-[4-[(Piperidin-4-
 yl)oxy]phenyl]-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916345-46-5P, tert-Butyl 4-[4-(4-ethyl-3-oxo-1-oxa-4,9-
 diazaspiro[5.5]undecan-9-yl)phenoxy]piperidine-1-carboxylate
 916345-47-6P, tert-Butyl 4-[4-[4-(6-fluoropyridin-3-yl)-3-oxo-1-oxa-4,9-
 diazaspiro[5.5]undecan-9-yl]phenoxy]piperidine-1-carboxylate
 916345-48-7P 916345-49-8P, 4-(6-Methoxypyridin-3-yl)-9-[4-[(piperidin-4-
 yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-50-1P
 916345-51-2P, 4-Cyclobutyl-9-[4-[[1-(tert-butoxycarbonyl)piperidin-4-
 yl]oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-52-3P,
 1-[4-(Benzyloxy)phenyl]-4-[(trimethylsilyl)oxy]piperidine-4-carbonitrile
 916345-53-4P, tert-Butyl 3-oxo-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-
 oxa-4,9-diazaspiro[5.5]undecan-4-carboxylate 916345-54-5P,
 5-Nitro-2-[(piperidin-4-yl)oxy]pyridine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of piperidine derivs. as histamine H3 receptor
 antagonists or inverse agonists)

IT 916338-43-7P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-
 benzofuran-1,4'-piperidine] 916338-45-9P, 4-Phenyl-1-[4-[3-(piperidin-1-
 yl)propoxy]phenyl]piperidin-4-ol 916338-47-1P, 3-Phenyl-8-[4-[3-
 (piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916338-49-3P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-
 benzofuran-1,4'-piperidine]-3-one 916338-51-7P, 4-Phenyl-9-[4-[3-
 (pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916338-53-9P, 9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-
 phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916338-55-1P,
 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-phenyl-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916338-58-4P 916338-61-9P,
 1-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyridin-3-yl)piperidin-4-ol
 trifluoroacetate 916338-64-2P, 4-(4-Methoxyphenyl)-1-[4-[3-(piperidin-1-
 yl)propoxy]phenyl]piperidin-4-ol trifluoroacetate 916338-67-5P,
 5-Fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-

1,4'-piperidine] trifluoroacetate 916338-70-0P, 5-Fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-73-3P, 7-Fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-76-6P, 5-Methoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-79-9P, 6-Methoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-82-4P, 7-Methoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-85-7P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1-one trifluoroacetate 916338-88-0P, 1-(Methylsulfonyl)-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916338-91-5P, 1-(Ethylsulfonyl)-7-fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916338-94-8P, 1-(Ethylsulfonyl)-5-fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916338-97-1P, 4-tert-Butoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916339-00-9P, 1-(Ethylsulfonyl)-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916339-03-2P, 3,3-Dimethyl-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine] trifluoroacetate 916339-06-5P, 3-Methyl-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine] trifluoroacetate 916339-09-8P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine] trifluoroacetate 916339-12-3P, Phenyl[1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidin-4-yl]methanone trifluoroacetate 916339-15-6P, 4-Phenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine-4-carbonitrile trifluoroacetate 916339-18-9P, 4-Benzyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine-4-carbonitrile trifluoroacetate 916339-21-4P, 4-Methyl-4-phenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine trifluoroacetate 916339-24-7P, 4,4-Diphenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine trifluoroacetate 916339-27-0P, 4-(3-Methoxyphenyl)-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidin-4-ol trifluoroacetate 916339-29-2P, 4-(4-Fluorophenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-31-6P, 4-(6-Fluoropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-33-8P, 4-(4-Methoxyphenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-35-0P, 4-(4-Methylphenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-37-2P, 4-(6-Methoxypyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-39-4P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(2-methylpyridin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-41-8P, 4-(3,4-Difluorophenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-43-0P, 4-(2,4-Difluorophenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-45-2P, 4-Phenyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-47-4P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-49-6P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-51-0P, 4-[6-(Difluoromethoxy)pyridin-3-yl]-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-53-2P, 4-(6-Propoxy)pyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-55-4P, 4-(6-Isopropoxy)pyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-57-6P, 4-[6-(Difluoromethoxy)pyridin-3-yl]-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-59-8P, 4-(2-Methoxypyrimidin-5-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-

4,9-diazaspiro[5.5]undecan-3-one 916339-61-2P 916339-63-4P,
 4-(6-Methoxyppyridin-3-yl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-
 4,9-diazaspiro[5.5]undecan-3-one 916339-65-6P, 4-(2-Methoxyppyridin-5-yl)-
 9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-67-8P, 4-(6-Methoxyppyridin-3-yl)-9-
 [4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-69-0P, 4-(4-Fluorophenyl)-9-[4-[3-
 ((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-71-4P, 4-(4-Methoxyphenyl)-9-[4-[3-
 ((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-73-6P, 4-(1,3-Benzodioxol-5-yl)-9-[4-
 [3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-75-8P, 4-(2-Methoxyppyridin-4-yl)-9-
 [4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-77-0P, 4-(1-Methyl-6-oxo-1,6-
 dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-
 1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-79-2P,
 4-(2-Methoxyppyridin-4-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-
 4,9-diazaspiro[5.5]undecan-3-one 916339-81-6P, 4-(1-Methyl-6-oxo-1,6-
 dihydropyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-83-8P, 9-[4-[3-((2R)-2-
 Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyridin-2-yl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-85-0P, 4-(5-Methylpyridin-2-yl)-9-[4-
 [3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-87-2P, 4-(4-Methylpyridin-2-yl)-9-[4-
 [3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-89-4P, 4-(3-Methylpyridin-2-yl)-9-[4-
 [3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-91-8P, 4-(5-Methoxyppyridin-2-yl)-9-
 [4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-93-0P, 4-(6-Methoxyppyridin-2-yl)-9-
 [4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-95-2P, 9-[4-[3-((2R)-2-
 Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(3-thienyl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-97-4P, 9-[4-[3-((2R)-2-
 Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(2-thienyl)-1-oxa-4,9-
 diazaspiro[5.5]undecan-3-one 916339-99-6P, 4-(4-Methoxyphenyl)-9-[4-[3-
 (pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916340-01-7P, 4-(6-Fluoropyridin-3-yl)-9-[4-[3-(pyrrolidin-1-
 yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-03-9P,
 4-[6-(Difluoromethoxy)pyridin-3-yl]-9-[4-[3-(pyrrolidin-1-
 yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-05-1P,
 5-[9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-
 diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916340-07-3P,
 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(1,3-thiazol-2-yl)-
 1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-09-5P,
 3-(4-Fluorophenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-
 diazaspiro[4.5]decan-2-one 916340-11-9P, 8-[4-[3-(Piperidin-1-
 yl)propoxy]phenyl]-3-(pyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-13-1P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-(pyridin-4-yl)-1-
 oxa-3,8-diazaspiro[4.5]decan-2-one 916340-15-3P, 3-(6-Fluoropyridin-3-
 yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-
 2-one 916340-17-5P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-[6-
 (trifluoromethyl)pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-19-7P, 3-(2-Fluorophenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-
 oxa-3,8-diazaspiro[4.5]decan-2-one 916340-21-1P, 3-(2-Fluoropyridin-4-
 yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-
 2-one 916340-23-3P, 3-[6-(Difluoromethyl)pyridin-3-yl]-8-[4-[3-
 (piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-25-5P, 3-(5-Fluoropyridin-2-yl)-8-[4-[3-(piperidin-1-
 yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-27-7P,
 3-(6-Fluoropyridin-2-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-
 diazaspiro[4.5]decan-2-one 916340-29-9P, 3-(3-Fluorophenyl)-8-[4-[3-
 (piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-31-3P, 3-(4-Methoxyphenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-
 1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-33-5P, 3-(3-Methoxyphenyl)-8-

[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-35-7P, 3-(6-Methoxypyridin-3-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-37-9P,
 3-(6-Methylpyridin-3-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-39-1P, 3-(2-Methoxyphenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-41-5P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-[4-(trifluoromethoxy)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916340-43-7P, 4-(1-Ethyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-45-9P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-47-1P,
 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-49-3P, 4-(3-Methoxypyridin-2-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-51-7P, 4-(1-Ethyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-53-9P,
 4-(1-Ethyl-5-methoxy-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-55-1P, 4-(5-Methoxypyridin-2-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-57-3P, 4-(5-Fluoropyridin-2-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-59-5P, 5-[9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916340-61-9P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(3-methylpyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-63-1P, 4-[1-(Difluoromethyl)-6-oxo-1,6-dihydropyridin-3-yl]-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-66-4P,
 4-(1-Isopropyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-69-7P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-72-2P,
 4-(3,4-Difluorophenyl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-74-4P, 4-(2,4-Difluorophenyl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-76-6P, 9-[4-[3-(Pyrrolidin-1-yl)propoxy]phenyl]-4-[6-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-78-8P, 4-(6-Isopropoxypyridin-3-yl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-80-2P,
 4-(2-Ethoxypyrimidin-5-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-82-4P, 4-(5-Methoxypyrazin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-84-6P,
 4-(4-Chlorophenyl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-86-8P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[4-(trifluoromethyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-88-0P, 4-[9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]benzonitrile 916340-90-4P,
 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-92-6P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-94-8P,
 4-(2-Methoxypyrimidin-5-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-97-1P, 4-(3-Methoxypyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-99-3P,
 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-01-0P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-03-2P,
 4-(1-Methyl-1H-pyrazol-3-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-05-4P,

4-(1-Methyl-1H-pyrazol-4-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-07-6P,
4-(5-Methoxypyridin-3-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-10-1P,
9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-12-3P, 4-(2-Methoxypyrimidin-5-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-14-5P, 5-[9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916341-16-7P,
4-(5-Methoxypyridin-3-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-18-9P,
4-(5-Methoxypyrazin-2-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-20-3P,
4-(1-Methyl-1H-pyrazol-4-yl)-9-[4-[3-((S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-22-5P,
3-Ethyl-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-24-7P, 8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-[4-(methylsulfonyl)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-26-9P, 3-(2-Ethoxypyrimidin-5-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-28-1P, 3-(1-Methyl-1H-pyrazol-4-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-30-5P, 3-(1-Methyl-1H-pyrazol-3-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-32-7P, 5-[8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916341-34-9P, 8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-36-1P, 3-(6-Methoxypyridin-3-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-38-3P, 3-(2-Methoxypyrimidin-5-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-40-7P, 3-(5-Methoxypyridin-3-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-42-9P, 3-(2-Methoxypyrimidin-5-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-44-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-46-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-methylpyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-48-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[6-(difluoromethoxy)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-50-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-52-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-isopropoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-54-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(2-isopropoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-56-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-58-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-60-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-62-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-64-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-66-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(imidazo[1,2-a]pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-68-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-70-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-72-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(3-methylpyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-74-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyridin-2-yl)-1-

oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-76-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-78-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-80-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(2-methoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-82-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-84-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(2-fluoropyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-86-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-88-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-90-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-92-9P, 5-[9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916341-94-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-96-3P, 4-Ethyl-9-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-98-5P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-00-2P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-02-4P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-04-6P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-06-8P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-08-0P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(3-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-10-4P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(2-methoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-12-6P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-14-8P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-16-0P, 5-[9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916342-18-2P, 4-(2-Ethoxypyrimidin-5-yl)-9-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-20-6P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-22-8P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-24-0P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(1-methyl-1H-pyrazol-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-26-2P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(1-methyl-1H-pyrazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-28-4P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(2-isopropoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-30-8P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-32-0P, 5-[9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916342-34-2P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-36-4P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-38-6P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(6-fluoropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-40-0P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(2-fluoropyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-42-2P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-[6-(difluoromethoxy)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

916342-44-4P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916342-46-6P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 916342-48-8P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-50-2P,
 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(2-methoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-52-4P,
 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(6-methylpyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-54-6P,
 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(5-methoxypyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-56-8P,
 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(6-methylpyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-58-0P, 5-[8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916342-60-4P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(pyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916342-62-6P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-64-8P,
 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-66-0P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-68-2P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(imidazo[1,2-a]pyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-70-6P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(3-methylpyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-72-8P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(6-fluoropyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-74-0P,
 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-[4-(methylsulfonyl)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-76-2P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(2-fluoropyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-78-4P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-80-8P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-82-0P, 3-Ethyl-8-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-84-2P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-86-4P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-88-6P, 5-[8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916342-90-0P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-92-2P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(5-methoxypyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-94-4P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-96-6P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(3-methoxypyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-98-8P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-00-5P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(5-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)

IT 916343-02-7P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(3-methylpyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916343-04-9P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-methoxypyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916343-06-1P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-fluoropyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
 916343-08-3P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-ethyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-10-7P,

8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2,2,2-trifluoroethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-12-9P
 , 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-[4-(methylsulfonyl)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-14-1P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2-ethoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-16-3P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-18-5P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-20-9P, 5-[8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916343-22-1P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-24-3P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-26-5P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-28-7P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-30-1P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-32-3P, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-methoxypyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-34-5P, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-36-7P, 5-[8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916343-38-9P, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-40-3P, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-42-5P, 4-(4-Methoxyphenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-44-7P, 4-(3-Methoxyphenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-46-9P, 4-(4-Fluorophenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-48-1P, 4-(6-Fluoropyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-50-5P, 4-(6-Methoxypyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-52-7P, 4-(6-Methoxypyrimidin-2-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-54-9P, 4-Methyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-56-1P, 4-Methyl-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-58-3P, 4-Ethyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-60-7P, 9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-62-9P, 4-Isopropyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-64-1P, 4-Isopropyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-67-4P, 4-(1-Ethylpropyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-68-5P, 9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-70-9P, 4-Cyclopropyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-72-1P, 4-Cyclobutyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-74-3P, 4-Cyclobutyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-76-5P, 4-Cyclopentyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-78-7P 916343-80-1P, 4-Benzyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-82-3P, 4-Benzyl-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

916343-84-5P, 4-Benzyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-86-7P, 4-(3-Fluorophenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-88-9P, 4-(2-Fluorophenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-90-3P, 4-(2-Fluoropyridin-4-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-92-5P, 4-Ethyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-94-7P, 4-Ethyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-96-9P, 4-Methyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-98-1P, 8-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-00-8P, 3-(4-Hydroxyphenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-02-0P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-04-2P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-06-4P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-fluoropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-07-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-08-6P, 9-[4-[(1-Cyclopropylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-10-0P, 4-Cyclobutyl-9-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-11-1P, 4-Cyclobutyl-9-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)


IT 346665-40-5P, tert-Butyl 4-[(5-nitropyridin-2-yl)oxy]piperidine-1-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)

RN 346665-40-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(5-nitro-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)





RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Apodaca, R	2004			EP-----1556046 A1	HCAPLUS
Apodaca, R	2004			US-0 @0 46 A1\$ 0	HCAPLUS *0
Apodaca, R	2004			WO--2004037257 A1	HCAPLUS
Apodaca, R	2004			JP--2006505590 A	
Banyu Pharmaceutical Co	2005			EP-----1642898 A1	HCAPLUS
Banyu Pharmaceutical Co	2005			AU--2004257025 A1	HCAPLUS
Banyu Pharmaceutical Co	2005			WO--2005007644 A1	HCAPLUS
Glaxo Group Ltd	2004			EP-----1567511 A1	HCAPLUS
Glaxo Group Ltd	2004			AU--2003280380 A1	HCAPLUS
Glaxo Group Ltd	2004			WO--2004035556 A1	HCAPLUS
Glaxo Group Ltd	2004			US-20060025404	HCAPLUS
Glaxo Group Ltd	2004			JP--2006508935 A	

L51 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:823314 HCAPLUS
 DN 143:211923
 TI Preparation of fused-ring 4-oxopyrimidine derivatives as histamine H3
 receptor antagonists or inverse agonists
 IN Nagase, Tsuyoshi; Sato, Nagaaki; Kanatani, Akio; Tokita,
 Shigeru
 PA Banyu Pharmaceutical Co., Ltd., Japan
 SO U.S. Pat. Appl. Publ., 84 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005182045	A1	20050818	2005US-0058444	20050214
	AU2005212092	A1	20050825	2005AU-0212092	20050214
	CA---2555824	A1	20050825	2005CA-2555824	20050214
	WO2005077905	A1	20050825	2005WO-JP02664	20050214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP---	1717230	A1	20061102	2005EP-0710446	20050214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN---	1918128	A	20070221	CN 2005-80004939	20050214
NO2006004089	A	20061106	2006NO-0004089	20060912	
PRAI	2004JP-0037190	A	20040213		
	2005WO-JP02664	W	20050214		
OS	MARPAT 143:211923				
GI					



AB The present invention provides fused-ring 4-oxopyrimidines (shown as I; variables defined below; e.g. 2-ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone (shown as II)) or pharmaceutically acceptable salts thereof, which, having histamine H3

receptor antagonist or inverse agonist activity, are useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. For I: e.g. Ar is a divalent group formed by eliminating two H atoms from benzene; X1 = N, S, or O; R1 is a 5- to 6-membered heteroaryl group; Ring A is a 5- to 6-membered heteroaryl ring; R2 and R3 are amino or alkylamino groups; Y = CH or N; and X2 = -(CH₂)_nNR₄R₅ (R₄ and R₅ are lower alkyl groups, and n = 2-4). Although the methods of preparation are not claimed, .apprx.275 example preps. are included. For example, II was prepared in 4 steps (98, 66, 82 and 47 %) starting from anthranilic acid and propionic anhydride and involving intermediates 2-ethyl-4H-3,1-benzoxazin-4-one, 2-ethyl-3-(4-hydroxyphenyl)-4(3H)-quinazolinone, and 2-ethyl-3-[4-(3-chloropropoxy)phenyl]-4(3H)-quinazolinone. Pharmacol. results are provided for II for the following tests: histamine analog coupling inhibition, antagonism of drinking behavior induced by R- α -methylhistamine (a histamine H₃ receptor selective agonist), in vitro kinetics, and brain/cerebrospinal fluid activity.

IC ICM A61K-031/55

ICS A61K-031/517; C07D-043/02

INCL 514217060; 514266200; 514266220; 544284000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 41151-73-9P, 3-[4-[3-(Diethylamino)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 41151-75-1P, 2-Methyl-3-[4-[2-(1-piperidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 862308-28-9P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-29-0P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-30-3P, 2-Methyl-3-[4-[3-(2-methyl-1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-31-4P, 3-[4-[3-(2,5-Dimethyl-1-pyrrolidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-32-5P, 2-Methyl-3-[4-[4-(1-piperidinyl)butoxy]phenyl]-4(3H)-quinazolinone 862308-33-6P, 3-[4-[3-(1-Azepanyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-34-7P, 3-[4-[3-(1-Azocanyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-35-8P, 2-Methyl-3-[4-[3-(2-methyl-1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-36-9P, 2-Methyl-3-[4-[3-(4-methyl-1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-37-0P 862308-38-1P, 2-Methyl-3-[4-[3-(3-methyl-1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-39-2P, 3-[4-[3-(3,5-Dimethyl-1-piperidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-40-5P, 2-Methyl-3-[3-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-41-6P, 3-[3-Bromo-4-[3-(1-piperidinyl)propoxy]phenyl]-2-ethyl-4(3H)-quinazolinone 862308-51-8P, 3-[4-[3-(1-Piperidinyl)propoxy]phenyl]-2-propyl-4(3H)-quinazolinone 862308-53-0P, 3-[4-[3-(1-Piperidinyl)propoxy]phenyl]-2-trifluoromethyl-4(3H)-quinazolinone 862308-55-2P, 2-Isopropyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-57-4P, 2,6-Dimethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-59-6P, 7-Chloro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-61-0P, 2,8-Dimethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-63-2P, 2-Ethyl-5-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-65-4P, 5-Fluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-73-4P, 5-Hydroxy-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone trifluoroacetate 862308-75-6P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-5-trifluoromethyl-4(3H)-quinazolinone 862308-78-9P, 7-Fluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-80-3P, 6-Fluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-82-5P, 6,7-Difluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-86-9P, 6-Chloro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-90-5P, 6,7-Dimethoxy-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-92-7P, 8-Chloro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-94-9P,

8-Methoxy-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-96-1P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]benzo[g]quinazolin-4(3H)-one 862308-98-3P, 2,6-Dimethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-02-2P, 2-Ethyl-5-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-04-4P, 5-Fluoro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-06-6P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-5-trifluoromethyl-4(3H)-quinazolinone 862309-08-8P, 5-Chloro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-10-2P, 2-Ethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-12-4P, 2,5-Dimethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-14-6P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862309-16-8P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862309-18-0P, 6-Chloro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-20-4P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-24-8P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-26-0P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-28-2P, 2-Methyl-3-[2-[3-(1-piperidinyl)propoxy]-5-pyrimidinyl]-4(3H)-quinazolinone 862309-32-8P, 2,5-Dimethyl-3-[2-[3-(1-piperidinyl)propoxy]-5-pyrimidinyl]-4(3H)-quinazolinone 862309-34-0P, 2-Ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862309-40-8P, 2-Ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-42-0P, 2-Ethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-44-2P, 2-Ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-46-4P, 2-Ethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-50-0P, 3-[4-[3-(1-Piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-59-9P, 6-(Butyrylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-61-3P, 6-(Hexanoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-63-5P, 6-(Benzoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-65-7P, 6-[(2-Phenylacetyl)amino]-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-67-9P, 6-(2-Naphthoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-69-1P, 2-Methyl-6-[(methylsulfonyl)amino]-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-71-5P, 2-Methyl-6-[(methylsulfonyl)amino]-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-75-9P, 7-(Acetyl amino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-77-1P, 7-(Butyrylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-81-7P, 7-(Hexanoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-83-9P, 7-(Benzoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-85-1P, 7-[(2-Phenylacetyl)amino]-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-87-3P, 7-(2-Naphthoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-89-5P, 6-[Acetyl(methyl)amino]-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-91-9P, 2-Methyl-6-phenyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-93-1P, 2-Methyl-6-(4-methylphenyl)-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-95-3P, 2-Methyl-6-(3-methylphenyl)-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-98-6P, 2-Methyl-6-(2-methylphenyl)-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862310-00-7P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-(3-pyridyl)-4(3H)-quinazolinone 862310-02-9P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-(4-pyridyl)-4(3H)-quinazolinone 862310-04-1P, 2-Methyl-5-phenyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862310-06-3P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-(2-pyridyl)-4(3H)-

quinazolinone 862310-08-5P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-15-4P,
 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-17-6P, 3-[4-[(1-Cyclohexyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-19-8P, 3-[4-[(1-Isopropyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-21-2P,
 3-[4-[(1-Ethyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-23-4P, 3-[4-[(1-Butyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-25-6P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-5-trifluoromethyl-4(3H)-quinazolinone 862310-35-8P,
 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2,5-dimethyl-4(3H)-quinazolinone 862310-37-0P, 7-Chloro-3-[4-[(1-cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-40-5P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2,6-dimethyl-4(3H)-quinazolinone 862310-42-7P,
 6-Chloro-3-[4-[(1-cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-44-9P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-6-methoxy-2-methyl-4(3H)-quinazolinone 862310-47-2P,
 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[2,3-d]pyrimidin-4(3H)-one 862310-50-7P,
 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862310-57-4P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862310-59-6P,
 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2,5-dimethyl-4(3H)-quinazolinone 862310-66-5P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methyl-5-trifluoromethyl-4(3H)-quinazolinone 862310-68-7P,
 5-Chloro-3-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-70-1P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862310-72-3P,
 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-ethylpyrido[4,3-d]pyrimidin-4(3H)-one 862310-74-5P,
 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[2,3-d]pyrimidin-4(3H)-one 862310-76-7P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-ethylpyrido[2,3-d]pyrimidin-4(3H)-one 862310-82-5P,
 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862310-84-7P,
 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-ethylpyrido[3,4-d]pyrimidin-4(3H)-one 862310-86-9P, 2-Phenyl-3-[4-[(3-(piperidin-1-yl)propoxy)phenyl]-4(3H)-quinazolinone 862310-88-1P,
 cis-2-Methyl-3-[4-[[4-(1-pyrrolidinyl)cyclohexyl]oxy]phenyl]-4(3H)-quinazolinone 862310-90-5P, trans-2-Methyl-3-[4-[[4-(1-pyrrolidinyl)cyclohexyl]oxy]phenyl]-4(3H)-quinazolinone 862310-94-9P,
 3-[4-[(1-Cyclopentyl-3-pyrrolidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-96-1P, 3-[4-[(1-Cyclobutyl-3-pyrrolidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-98-3P,
 3-[4-[(1-Cyclopentyl-4-azepanyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-01-1P, 3-[4-[(1-Cyclobutyl-4-azepanyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-03-3P,
 3-Methyl-2-[4-[(3-(1-piperidinyl)propoxy)phenyl]-1(2H)-isoquinolinone 862311-11-3P, 2-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl-1(2H)-isoquinolinone 862311-13-5P,
 2-Methyl-3-[4-[[trans-3-(1-pyrrolidinyl)cyclopentyl]oxy]phenyl]-4(3H)-quinazolinone 862311-19-1P, 862311-21-5P,
 3-[4-[(3-(8-Azabicyclo[3.2.1]oct-8-yl)propoxy)phenyl]-2-methyl-4(3H)-quinazolinone 862311-24-8P,
 3-[4-[(3,3-Difluoropiperidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-27-1P,
 3-[4-[(3-(3R)-3-Fluoropiperidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-31-7P,
 3-[4-[(3-(4,4-Difluoropiperidin-1-yl)propoxy)phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-34-0P,
 3-[4-[(3-(4-Fluoropiperidin-1-yl)propoxy)phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-37-3P,
 3-[4-[(3-(3,3-Difluoropiperidin-1-yl)propoxy)phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-41-9P,
 3-[4-[(3-(3-Fluoropiperidin-1-yl)propoxy)phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-44-2P,
 2-Methyl-3-[4-[(3R)-3-methylpiperidin-1-yl]propoxy]phenyl]-4(3H)-quinazolinone 862311-47-5P 862311-49-7P,

2-Methyl-3-[4-[3-(3-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-51-1P, 5-Methoxy-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]-2-propyl-4(3H)-quinazolinone 862311-53-3P, 5-Methoxy-2-propyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-55-5P, 2-Methyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-62-4P, 2,5-Dimethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-64-6P, 2,6-Dimethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-66-8P, 2-Ethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-68-0P, 6-Chloro-2-ethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862311-72-6P, 6-Methoxy-2-methyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-74-8P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-82-8P, 5-Bromo-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-84-0P, 5-Fluoro-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-86-2P, 2-Ethyl-5-fluoro-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-88-4P, 6-Fluoro-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862311-91-9P, 2-Ethyl-6-fluoro-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862311-97-5P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one monohydrochloride 862312-00-3P, 2-Ethyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one monohydrochloride 862312-02-5P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862312-03-6P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one monotosylate 862312-05-8P, 2-Ethyl-5-methoxy-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone hydrochloride 862312-07-0P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862312-09-2P, 2-Ethyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862312-11-6P, 8-Fluoro-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone hydrochloride 862312-13-8P, 8-Fluoro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone hydrochloride 862312-15-0P, 6-(2-Fluoroethoxy)-2-methyl-3-[4-(piperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-17-2P, 6-(2-Fluoroethoxy)-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-19-4P, 5-Methoxy-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-23-0P, 6-Methoxy-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-25-2P, 6-(Difluoromethoxy)-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-29-6P, 5-(Difluoromethoxy)-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-31-0P, 7-Methoxy-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-33-2P, 7-Methoxy-2-methyl-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-36-5P, 7-Methoxy-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-38-7P, 5-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-43-4P, 6-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-46-7P, 7-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-48-9P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-2,6-dimethyl-4(3H)-quinazolinone 862312-50-3P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-5-fluoro-2-methyl-4(3H)-quinazolinone 862312-54-7P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-7-fluoro-2-methyl-4(3H)-quinazolinone 862312-56-9P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-5-methoxy-2-methyl-4(3H)-quinazolinone 862312-58-1P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-6-methoxy-2-methyl-4(3H)-quinazolinone 862312-60-5P 862312-64-9P, 3-[4-[3-(Azepan-1-

yl)propoxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one
862312-66-1P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-68-3P,
2,5-Dimethyl-3-[2-methoxy-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862312-78-5P, 6-Fluoro-3-[2-methoxy-4-[3-(1-piperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one
862312-80-9P, 6-Fluoro-3-[2-methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862312-82-1P,
3-[2-Methoxy-4-[3-(piperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862312-84-3P, 3-[2-Methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one
862312-88-7P, 3-[3-Bromo-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone 862312-94-5P, 2,5-Dimethyl-3-[2-(2-fluoroethoxy)-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone
862312-98-9P, 3-[2-(2-Fluoroethoxy)-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-00-6P,
3-[2-(2-Fluoroethoxy)-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862313-06-2P,
6-Methoxy-2-methyl-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862313-08-4P, 6-Methoxy-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one
862313-10-8P, 2-Ethyl-6-methoxy-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862313-12-0P, 2-Ethyl-6-methoxy-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one
862313-14-2P, 6-Methoxy-3-[2-methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-20-0P,
3-[2-(2-Fluoroethoxy)-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-6-methoxycarbonyl-2-methyl-4(3H)-quinazolinone 862313-22-2P,
3-[3-Fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862313-24-4P, 3-[2-Fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862313-26-6P,
2-Methyl-3-[3-methyl-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862313-28-8P
, 2-Methyl-3-[2-methyl-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone
862313-30-2P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-2-methoxyphenyl]-2,5-dimethyl-4(3H)-quinazolinone 862313-32-4P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-methoxy-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one
862313-34-6P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]phenyl]-6-methoxy-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-40-4P,
3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-3-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-42-6P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]-3-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-44-8P,
3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-2-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-46-0P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]-2-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-48-2P,
2-Methyl-3-[4-[(1-cyclobutylpiperidin-4-yl)oxy]-2-methylphenyl]-4(3H)-quinazolinone hydrochloride 862313-50-6P, 2-Methyl-3-[4-[(1-cyclopentylpiperidin-4-yl)oxy]-2-methylphenyl]-4(3H)-quinazolinone
862313-52-8P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]-2-(2-fluoroethoxy)phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one
862313-54-0P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-5-(2-fluoroethoxy)-2-methyl-4(3H)-quinazolinone 862313-58-4P,
3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-2-(2-fluoroethoxy)phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-60-8P,
3-[2-[(1-Cyclobutylpiperidin-4-yl)oxy]pyrimidin-5-yl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone 862313-68-6P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-5-methoxy-2-propyl-4(3H)-quinazolinone 862313-72-2P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-6-fluoropyrido[3,4-d]pyrimidin-4(3H)-one
862313-74-4P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-fluoro-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-76-6P,
3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-5-fluoro-2-methyl-4(3H)-quinazolinone 862313-78-8P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-fluoro-2-methyl-4(3H)-quinazolinone 862313-80-2P,
3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-7-fluoro-2-methyl-4(3H)-quinazolinone 862313-82-4P, 3-[4-[(1-Cyclobutylpiperidin-4-

yl)oxy]phenyl]-6,7-difluoro-2-methyl-4(3H)-quinazolinone 862313-84-6P,
 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-methyl-4(3H)-
 quinazolinone 862313-86-8P, 3-[4-[(1-Cyclobutylpiperidin-4-
 yl)oxy]phenyl]-2-ethyl-5-fluoro-4(3H)-quinazolinone 862313-88-0P,
 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-methoxy-4(3H)-
 quinazolinone 862313-90-4P, 5-Chloro-3-[4-[(1-cyclobutylpiperidin-4-
 yl)oxy]phenyl]-2-ethyl-4(3H)-quinazolinone 862313-92-6P,
 3-[3-Bromo-4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-5-fluoro-2-methyl-
 4(3H)-quinazolinone 862313-94-8P, 3-[3-Bromo-4-[(1-cyclobutylpiperidin-4-
 yl)oxy]phenyl]-2,5-dimethyl-4(3H)-quinazolinone 862313-98-2P,
 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-(trifluoromethyl)-
 4(3H)-quinazolinone hydrochloride 862314-00-9P, 3-[4-[(1-
 Cyclobutylpiperidin-4-yl)oxy]phenyl]-8-fluoro-2-methyl-4(3H)-quinazolinone
 862314-02-1P, 2-[3-(Benzyloxy)propyl]-3-[4-[(1-cyclopentylpiperidin-4-
 yl)oxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862314-08-7P,
 2-[2-(Allyloxy)ethyl]-6-chloro-3-[4-[(1-cyclobutylpiperidin-4-
 yl)oxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-16-7P,
 3-[4-[(1-Cyclopropylpiperidin-4-yl)oxy]phenyl]-2-methylpyrido[3,4-
 d]pyrimidin-4(3H)-one 862314-18-9P, 3-[4-[(1-Cyclobutylpiperidin-4-
 yl)oxy]phenyl]-6-(difluoromethoxy)-2-methyl-4(3H)-quinazolinone
 862314-20-3P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-7-methoxy-2-
 methyl-4(3H)-quinazolinone 862314-26-9P, 6-Chloro-3-[2-(2-fluoroethoxy)-
 4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-
 d]pyrimidin-4(3H)-one 862314-28-1P, 2-Ethyl-6-methoxy-3-[4-[3-((2S)-2-
 methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one
 862314-30-5P, 2-Ethyl-6-methoxy-3-[4-[3-((3S)-3-methylpiperidin-1-
 yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one hydrochloride
 862314-32-7P, 6-Methoxy-3-[2-methoxy-4-[3-((3S)-3-methylpiperidin-1-
 yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one
 862314-36-1P, 6-Methoxy-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-
 yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-37-2P,
 6-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-
 yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-39-4P,
 2,5-Dimethyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-
 quinazolinone 862314-40-7P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-
 yl)propoxy]phenyl]-5-(trifluoromethyl)-4(3H)-quinazolinone 862314-41-8P,
 5-Chloro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-
 4(3H)-quinazolinone 862314-42-9P, 5-Fluoro-2-methyl-3-[4-[3-((2R)-2-
 methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-43-0P,
 6-Fluoro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-
 4(3H)-quinazolinone 862314-44-1P, 7-Fluoro-2-methyl-3-[4-[3-((2R)-2-
 methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-45-2P,
 8-Fluoro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-
 4(3H)-quinazolinone 862314-46-3P, 2,6-Dimethyl-3-[4-[3-((2R)-2-
 methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-47-4P,
 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[2,3-
 d]pyrimidin-4(3H)-one 862314-48-5P, 2-Methyl-3-[4-[3-((2R)-2-
 methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one
 862314-49-6P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-
 yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of fused ring 4-oxypyrimidine derivs. as
 histamine H3 receptor antagonists or inverse agonists)

IT 1022-46-4P, 2-Phenyl-4H-3,1-benzoxazin-4-one 1462-86-8P,
 3-Aminopyridine-2-carboxylic acid 2852-91-7P, 2-(2-Oxopropyl)benzoic
 acid 2916-09-8P, 2-Ethyl-4H-3,1-benzoxazin-4-one 6760-99-2P
 16750-67-7P, 4-Amino-2-bromophenol 22428-87-1P, 1,4-Dioxaspiro[4.5]decan-
 8-ol 38527-50-3P, 6-Methoxy-2-methyl-4H-3,1-benzoxazin-4-one
 38876-67-4P, 2-Bromo-6-nitrobenzoic acid 60288-19-9P,
 2,5-Dimethyl-4H-3,1-benzoxazin-4-one 66122-70-1P, 3-Methyl-1H-isochroman-
 1-one 92374-75-9P, 1-[3-(4-Nitrophenoxy)propyl]piperidine 99059-02-6P,
 3-(1-Hydroxyethyl)-2-benzofuran-1(3H)-one 155619-00-4P,
 2-Ethyl-3-(4-hydroxyphenyl)-4(3H)-quinazolinone 162402-39-3P,
 4-(4-Nitrophenoxy)piperidine 251552-34-8P, 4-[3-(1-

Piperidinyl)propoxy]aniline 343965-79-7P, 4-[3-(1-Pyrrolidinyl)propoxy]aniline 834878-12-5P, (2S)-2-Methylpyrrolidine hydrobromide 862308-27-8P, 2-Ethyl-3-[4-(3-chloropropoxy)phenyl]-4(3H)-quinazolinone 862308-42-7P, 2-Bromo-1-(3-chloropropoxy)-4-nitrobenzene 862308-44-9P, 3-Bromo-4-(3-chloropropoxy)aniline 862308-45-0P, 3-[3-Bromo-4-(3-chloropropoxy)phenyl]-2-ethyl-4(3H)-quinazolinone 862308-49-4P, 5-Amino-2-[3-(1-piperidinyl)propoxy]pyrimidine 862309-00-0P, 4-[3-(1-Pyrrolidinyl)propoxy]aniline ditosylate 862309-30-6P, 5-Nitro-2-[3-(piperidin-1-yl)propoxy]pyrimidine 862309-55-5P, 6-Amino-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862310-10-9P, 3-[4-[(1-tert-Butoxycarbonyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-13-2P, 2-Methyl-3-[4-(4-piperidinyloxy)phenyl]-4(3H)-quinazolinone 862310-27-8P, 1-Cyclopentyl-4-(4-nitrophenoxy)piperidine 862310-29-0P, 4-[(1-Cyclopentylpiperidin-4-yl)oxy]aniline 862310-31-4P, 2-Methyl-5-trifluoromethyl-4H-3,1-benzoxazin-4-one 862310-33-6P, 4-[(1-Cyclobutyl-4-piperidinyl)oxy]aniline 862310-62-1P, 4-[(1-Cyclobutyl-4-piperidinyl)oxy]aniline monotosylate 862310-92-7P, 2-Methyl-3-[4-[(4-oxocyclohexyl)oxy]phenyl]-4(3H)-quinazolinone 862311-07-7P, 2-(4-Methoxyphenyl)-3-methyl-1(2H)-isoquinolinone 862311-09-9P, 2-(4-Hydroxyphenyl)-3-methyl-1(2H)-isoquinolinone 862311-15-7P, 3-[4-[(3-Hydroxycyclopentyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-17-9P, 3-[4-[(3-[(Methylsulfonyl)oxy]cyclopentyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-57-7P, 3-((2S)-2-Methylpyrrolidin-1-yl)propan-1-ol 862311-60-2P, 4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]aniline 862311-76-0P, 3-((3S)-3-Methylpiperidin-1-yl)propan-1-ol 862311-80-6P, 4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]aniline monotosylate 862312-41-2P, 4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]aniline monotosylate 862312-92-3P, 6-Chloro-3-[2-hydroxy-4-[3-(piperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-62-0P, tert-Butyl 4-[(5-nitropyrimidin-2-yl)oxy]piperidine-1-carboxylate 862313-64-2P, tert-Butyl 4-[(5-aminopyrimidin-2-yl)oxy]piperidine-1-carboxylate 862313-66-4P, 2-Methyl-3-[2-(piperidin-4-yloxy)pyrimidin-5-yl]-5-(trifluoromethyl)-4(3H)-quinazolinone 862314-04-3P, 2-[[4-(Benzyloxy)butanoyl]amino]nicotinic acid 862314-06-5P, 2-[3-(Benzyloxy)propyl]-4H-pyrido[2,3-d][1,3]oxazin-4-one 862314-14-5P, 1-Cyclopropyl-4-(4-nitrophenoxy)piperidine 862314-60-1P, 4-[3-(Pyrrolidin-1-yl)butoxy]aniline 862314-67-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused ring 4-oxopyrimidine derivs. as histamine H3 receptor antagonists or inverse agonists)


IT 862313-60-8P, 3-[2-[(1-Cyclobutylpiperidin-4-yl)oxy]pyrimidin-5-yl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused ring 4-oxopyrimidine derivs. as histamine H3 receptor antagonists or inverse agonists)



RN 862313-60-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[2-[(1-cyclobutyl-4-piperidinyl)oxy]-5-pyrimidinyl]-2-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



DN 142:176868
 TI Preparation of heterocyclic compounds as histamine H3 receptor antagonists/inverse agonists
 IN Ohtake, Norikazu; Naya, Akira; Yuji; Jitsuoka, Makoto; Suga, Takuya; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio
 PA Banyu Pharmaceutical Co., Ltd, Japan
 SO PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005007644	A1	20050127	2004WO-JP09272	20040624 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2004257025	A1	20050127	2004AU-0257025	20040624 <--
	CA---2529790	A1	20050127	2004CA-2529790	20040624 <--
	EP---1642898	A1	20060405	2004EP-0746741	20040624 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN---1812981	A	20060802	CN 2004-80018205	20040624 <--
	US2006178375	A1	20060810	2005US-0561115	20051215 <--
PRAI	2003JP-0184879	A	20030627	<--	
	2004WO-JP09272	W	20040624	<--	
OS	MARPAT 142:176868				
GI					



AB The title compds. I [each of X1, X2 and X3 independently represents N or CH; W represents the formula T1, etc.; m = 0 - 3; and Y represents (O)jL1(CO)p(M)iQ1; j, p, i = 0 or 1; L1 = alkylene, single bond; M = O, etc.; Q1 = cyano, etc; R = cyano, etc.] are prepared. Thus, 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine was prepared in a multistep process from 2-chloro-5-bromopyrimidine and 1-tert-butoxycarbonyl-4-hydroxypiperidine. In an in vitro assay for inhibition of a histamine analog binding to the H3 receptors, compds. of this invention showed IC50 values of 0.45 nM to 1.9 nM. Processes for preparing I are disclosed. Formulations are given.

IC ICM C07D-401/12
 ICS C07D-401/14; C07D-403/12; C07D-405/14; C07D-409/14; C07D-413/14; C07D-487/04; A61K-031/506; A61K-031/4545; A61K-031/501; A61P-001/16; A61P-003/00; A61P-003/04; A61P-003/06; A61P-003/10; A61P-007/00; A61P-009/10; A61P-009/12; A61P-013/12; A61P-019/06

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

IT 832735-10-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

IT 832734-48-2P 832734-50-6P 832734-53-9P 832734-55-1P 832734-57-3P
832734-59-5P 832734-60-8P 832734-62-0P 832734-64-2P 832734-66-4P
832734-68-6P 832734-70-0P 832734-72-2P 832734-74-4P 832734-76-6P
832734-78-8P 832734-80-2P 832734-82-4P 832734-84-6P
832734-85-7P 832734-86-8P 832734-87-9P 832734-88-0P
832734-89-1P 832734-90-4P 832734-91-5P 832734-92-6P 832734-93-7P
832734-94-8P 832734-95-9P 832734-96-0P 832734-97-1P 832734-98-2P
832734-99-3P 832735-00-9P 832735-01-0P 832735-02-1P 832735-03-2P
832735-04-3P 832735-05-4P 832735-06-5P 832735-07-6P 832735-08-7P
832735-09-8P 832735-11-2P 832735-12-3P 832735-13-4P 832735-14-5P
832735-15-6P 832735-16-7P 832735-17-8P 832735-18-9P 832735-19-0P
832735-20-3P 832735-21-4P 832735-22-5P 832735-23-6P 832735-24-7P
832735-25-8P 832735-26-9P 832735-27-0P 832735-28-1P 832735-29-2P
832735-30-5P 832735-31-6P 832735-32-7P 832735-33-8P 832735-34-9P
832735-35-0P 832735-36-1P 832735-38-3P 832735-39-4P 832735-40-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

IT 52240-10-5P, 6-(4-Cyanophenyl)-2H-pyridazin-3-one 832735-41-8P
832735-42-9P 832735-43-0P 832735-44-1P 832735-45-2P 832735-46-3P
832735-47-4P 832735-48-5P 832735-49-6P 832735-50-9P
832735-51-0P 832735-52-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)


IT 832735-10-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

RN 832735-10-1 HCAPLUS

CN Piperidine, 1-[[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abbott Laboratories	2002			WO-----0206223 A1	HCAPLUS
Abbott Laboratories	2002			EP-----1301480 A1	HCAPLUS
Abbott Laboratories	2002			BR---200108088 A	
Abbott Laboratories	2002			AU---200173384 A	
Abbott Laboratories	2002			MX--2002012851 A1	
Abbott Laboratories	2002			JP--2004509076 A	
Astrazeneca Ab	2001			WO-----0177101 A1	HCAPLUS
Astrazeneca Ab	2001			EP-----1274701 A1	HCAPLUS
Astrazeneca Ab	2001			CN-----1433411 A	HCAPLUS
Astrazeneca Ab	2001			BR---200109922 A	
Astrazeneca Ab	2001			AU---200146997 A	

Astrazeneca Ab	2001	US-0 @0 97 A \$ 0	#3	x f!E *0
Astrazeneca Ab	2001	MX--2002009885 A1		
Astrazeneca Ab	2001	NO--200204774 A		
Astrazeneca Ab	2001	ZA--200207700 A		
Astrazeneca Ab	2001	KR--2003005264 A		
Astrazeneca Ab	2001	JP--2003530393 A		
Astrazeneca Ab	2001	US-0 @0 93 A \$ 0	#3	x f!E *0
Astrazeneca Ab	2001	US-0 @0 93 A \$ 0	#3	x f!, *0
Astrazeneca Ab	2001	US-----6525070 B2		HCAPLUS
Neurogen Corp	2001	WO-----0160806 A2		HCAPLUS
Neurogen Corp	2001	EP-----1255740 A2		HCAPLUS
Neurogen Corp	2001	CN-----1400970 A		
Neurogen Corp	2001	BR----20008363 A		
Neurogen Corp	2001	AU--200138494 A		
Neurogen Corp	2001	MX--2002007868 A1		
Neurogen Corp	2001	SK--200201154 A3		
Neurogen Corp	2001	CZ--200202739 A3		
Neurogen Corp	2001	NO--200203869 A		
Neurogen Corp	2001	ZA--200206103 A		
Neurogen Corp	2001	US-0 @0 03 A \$ 0	#3	x f!E *0
Neurogen Corp	2001	HU--200301573 A2		HCAPLUS
Neurogen Corp	2001	KR--2003031886 A		
Neurogen Corp	2001	JP--2004500383 A		
Novo Nordisk AS	2003	WO----03024929 A1		HCAPLUS
Novo Nordisk AS	2003	EP-----1430027 A2		HCAPLUS
Novo Nordisk AS	2003	EP-----1434765 A1		HCAPLUS
Novo Nordisk AS	2003	AU--2002328797 A1		
Novo Nordisk AS	2003	US-0 @0 97 A1\$ 0	#3	x f!E *0
Ortho-McNeil Pharmaceut	2002	WO-----0010997 A1		HCAPLUS
Ortho-McNeil Pharmaceut	2002	EP---11079665 A1		
Ortho-McNeil Pharmaceut	2002	US-0 @0 65 A1\$ 0	#3	x f!t *0
Ortho-McNeil Pharmaceut	2002	JP--2002523413 A		
Ortho-McNeil Pharmaceut	2002	US-----6562847 B1		HCAPLUS
Ortho-McNeil Pharmaceut	2002	AU-----9955747 A		HCAPLUS

=> d his

(FILE 'HCAPLUS' ENTERED AT 12:36:19 ON 22 JUN 2007)
DEL HIS Y

FILE 'HCAPLUS' ENTERED AT 14:13:31 ON 22 JUN 2007
L1 1 US20060178375/PN OR (US2005-561115 OR JP2003-184879 OR WO2004-J

FILE 'HCAPLUS' ENTERED AT 14:15:00 ON 22 JUN 2007

FILE 'STNGUIDE' ENTERED AT 14:16:00 ON 22 JUN 2007

FILE 'REGISTRY' ENTERED AT 14:16:29 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 14:16:30 ON 22 JUN 2007
L2 TRA L1 1- RN : 145 TERMS

FILE 'REGISTRY' ENTERED AT 14:16:30 ON 22 JUN 2007
L3 145 SEA L2
L4 103 L3 AND NR>=2
L5 970 C15H20N4O
L6 11 L5 AND NC5/ES AND NCNC3/ES
L7 0 L6 AND L3
L8 0 L5 AND L3

FILE 'STNGUIDE' ENTERED AT 14:18:25 ON 22 JUN 2007

FILE 'REGISTRY' ENTERED AT 14:23:32 ON 22 JUN 2007
L9 STR
L10 50 L9

L11 51529 L9 FULL
 L12 STR L9
 L13 50 L12
 L14 50 L12 SAM SUB=L11
 L15 47061 L12 FULL SUB=L11
 L16 4468 L11 NOT L15
 L17 STR L9
 L18 40 L17 SAM SUB=L16
 L19 STR L17
 L20 28 L19 SAM SUB=L16

FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 22 JUN 2007

FILE 'REGISTRY' ENTERED AT 14:47:48 ON 22 JUN 2007

L21 491 L19 FULL SUB=L16
 SAV TEM L21 J115S1/A
 SAV TEM L16 J115BC1/A
 L22 STR L19
 L23 5 L22 SAM SUB=L16
 L24 120 L22 FULL SUB=L16
 SAV TEM J115S2/A L24
 L25 610 L21,L24

FILE 'STNGUIDE' ENTERED AT 14:52:23 ON 22 JUN 2007

FILE 'REGISTRY' ENTERED AT 14:53:49 ON 22 JUN 2007

L26 5 L25 AND L3

FILE 'STNGUIDE' ENTERED AT 14:55:04 ON 22 JUN 2007

FILE 'REGISTRY' ENTERED AT 14:56:03 ON 22 JUN 2007

L27 STR L22
 L28 5 L27 SAM SUB=L11
 L29 127 L27 FULL SUB=L11
 SAV TEM J115S3/A L29
 L30 622 L25,L29
 L31 5 L30 AND L3

FILE 'HCAPLUS' ENTERED AT 14:57:57 ON 22 JUN 2007

L32 63 L30
 E OHTAKE N/AU
 L33 74 E3,E16
 E NORIZAKU O/AU
 E E NAYA A/AU
 E NAYA A/AU
 L34 25 E3,E5
 E NAYA N/AU
 E AKIRA N/AU
 L35 3 E9
 E HAGA Y/AU
 L36 394 E3-6
 E HAGA YUGI/AU
 E HAGA YUJI/AU
 L37 20 E3
 E HAGA N/AU
 L38 7 E5
 E YUJI H/AU
 E YUJI N/AU
 L39 17 E6
 E JITSUOKA M/AU
 L40 12 E4
 E JITSUOKA N/AU
 E E MAKOTO J/AU
 E SUGA T/AU
 L41 170 E3-4
 E SUGA TAKUYA/AU

L42 5 E3
 E SUGA N/AU
 L43 5 E3,E7
 E TAKUYA S/AU
 E TAKUYA N/AU
 E YOSHIMOTO R/AU
 L44 21 E3,E6-7
 E YOSHIMOTO N/AU
 L45 71 E3-4
 E RYO Y/AU
 E RYO N/AU
 E TOKITA S/AU
 L46 60 E3,E14
 E TOKITA N/AU
 L47 3 E5
 E SHIGERU T/AU
 E KANATANI A/AU
 L48 105 E3-5
 E KANATANI N/AU
 L49 1 E3
 E AKIO K/AU
 E AKIKO K/AU
 E AKIKO N/AU
 E AKIO N/AU
 L50 1824 (BANYU OR BAN YU)/CS,PA

FILE 'STNGUIDE' ENTERED AT 15:05:17 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:06:44 ON 22 JUN 2007

L51 3 L32 AND L1,L33-50

L52 60 L32 NOT L51

FILE 'STNGUIDE' ENTERED AT 15:07:50 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:08:49 ON 22 JUN 2007

FILE 'STNGUIDE' ENTERED AT 15:10:15 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:12:27 ON 22 JUN 2007

FILE 'STNGUIDE' ENTERED AT 15:12:52 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:16:13 ON 22 JUN 2007

L53 44 L52 AND (PD<=20040624 OR AD<=20040624 OR PRD<=20040624)

FILE 'STNGUIDE' ENTERED AT 15:17:55 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:21:50 ON 22 JUN 2007

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 15:22:33 ON 22 JUN 2007

L54 448 E1-448

FILE 'STNGUIDE' ENTERED AT 15:26:44 ON 22 JUN 2007

FILE 'REGISTRY' ENTERED AT 16:09:26 ON 22 JUN 2007

FILE 'HCAPLUS' ENTERED AT 16:09:49 ON 22 JUN 2007

=> => b reg

FILE 'REGISTRY' ENTERED AT 16:19:40 ON 27 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JUN 2007 HIGHEST RN 939408-72-7

DICTIONARY FILE UPDATES: 26 JUN 2007 HIGHEST RN 939408-72-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 15

L1 STR



VAR G1=C/N

REP G2=(0-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L2 (51529)SEA FILE=REGISTRY SSS FUL L1

L3 STR



REP G2=(0-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L4 (47061)SEA FILE=REGISTRY SUB=L2 SSS FUL L3

L5 4468 SEA FILE=REGISTRY ABB=ON PLU=ON L2 NOT L4

=> b hcap

FILE 'HCAPLUS' ENTERED AT 16:19:47 ON 27 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jun 2007 VOL 147 ISS 1

FILE LAST UPDATED: 26 Jun 2007 (20070626/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitr 117 tot

L17 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:513745 HCAPLUS

DN 145:1056

TI Treatment of stroke with histamine H3 inverse agonists or histamine H3 antagonists

IN Seabrook, Guy R.; Koblan, Ken S.; Ho, Tony Wei-Hsiu

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2006058023	A2	20060601	2005WO-US42365	20051118
	WO2006058023	A3	20060914		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI 2004US-630513P P 20041123

AB Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with an anti-stroke agent, for treating stroke.

Preparation of histamine H3 inverse agonist 2-(1-cyclopentylpiperidine-4-yloxy)-5-(4-cyanophenyl)pyrimidine is included.


IT 832734-48-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(histamine H3 inverse agonists and histamine H3 antagonists for treatment of stroke, and use with other agents)

RN 832734-48-2 HCAPLUS

CN Benzonitrile, 4-[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1288664 HCAPLUS

DN 144:36366

TI Preparation of quinazoline derivatives as histamine H3 receptor antagonists

IN Mizutani, Takashi; Nagase, Tsuyoshi; Sato, Nagaaki; Kanatani, Akio; Tokita, Shigeru

PA Banyu Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 233 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005115993	A1	20051208	2005WO-JP10291	20050530
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU2005247808	A1	20051208	2005AU-0247808	20050530
CA---2569081	A1	20051208	2005CA-2569081	20050530
EP---1757594	A1	20070228	2005EP-0745824	20050530
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV			
CN---1960977	A	20070509	CN 2005-80017630	20050530
PRAI 2004JP-0162459	A	20040531		
2005WO-JP10291	W	20050530		
OS MARPAT 144:36366				
GI				




AB Title compds. I [R1 = aryl, aralkyl, alkoxy, etc.; further details on R1 are given.; R2, R3 = H, amino, alkylamino, etc.; R4 = Q1, etc.; R5 = H, alkyl, hydroxy, etc.; R7, R8 = alkyl, arylalkyl, heteroarylalkyl, with the proviso that R7 and R8 are not alkyl simultaneously; X1 = NH, O, S; Y = N, C; Ar = optionally substituted aryl, heteroaryl with alkyl, alkoxy, halo; ring A = Ph, heteroaryl containing N, O] were prepared. For example, reaction of 2-(4-hydroxyphenyl)-3,8-dimethyl-4(3H)-quinazolinone, e.g., prepared from 3-methyl-2-aminobenzoic acid in 3 steps, with 1-chloro-3-bromopropane and K2CO3 followed by in-situ treatment with piperidine afforded compound II [R = methyl; X = piperidin-1-yl]. In histamine analog binding inhibition assays, the IC50 value of compound II [R = H; X = pyrrolidin-1-yl] was 0.68 nM. Compds. I are claimed useful for the treatment of diabetes, obesity, etc.

IT 870997-73-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as histamine H3 antagonists for treatment of obesity, diabetes, etc.)

RN 870997-73-2 HCAPLUS

CN Pyridine, 2-[(1-cyclobutyl-4-piperidinyl)oxy]-5-ethenyl- (9CI) (CA INDEX NAME)



RE.CNT 55. THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1123759 HCAPLUS

DN 143:379851

TI Treatment of tremor or other movement disorder with histamine H3 inverse agonists or histamine H3 antagonists

IN Marino, Michael J.; Seabrook, Guy R.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO2005097111 A2 20051020 2005WO-US09562 20050322
 WO2005097111 A3 20060427
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP---1732544 A2 20061220 2005EP-0732633 20050322
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 PRAI 2004US-556803P P 20040326
 2004US-561188P P 20040409
 2004US-629099P P 20041118
 2005WO-US09562 W 20050322
 AB Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as essential tremor, and tremor associated with Parkinson's disease, cranofacial trauma, multiple sclerosis, stroke, dystonia, and neuropathic, toxic or drug-induced tremor. Preparation and activity of 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine is included.
 IT 832734-48-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (histamine h3 inverse agonists or antagonists for treatment of tremor or other movement disorder, and use with other agents)
 RN 832734-48-2 HCAPLUS
 CN Benzonitrile, 4-[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:74112 HCAPLUS
 DN 142:176868
 TI Preparation of heterocyclic compounds as histamine H3 receptor antagonists/inverse agonists
 IN Ohtake, Norikazu; Naya, Akira; Haga, Yuji; Jitsuoka, Makoto; Suga, Takuya; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio
 PA Banyu Pharmaceutical Co., Ltd, Japan
 SO PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005007644	A1	20050127	2004WO-JP09272	20040624
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG



AU2004257025 A1 20050127 2004AU-0257025 20040624
 CA---2529790 A1 20050127 2004CA-2529790 20040624
 EP---1642898 A1 20060405 2004EP-0746741 20040624

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN---1812981 A 20060802 CN 2004-80018205 20040624
 US2006178375 A1 20060810 2005US-0561115 20051215

PRAI 2003JP-0184879 A 20030627
 2004WO-JP09272 W 20040624

OS MARPAT 142:176868
 GI



AB The title compds. I [each of X1, X2 and X3 independently represents N or CH; W represents the formula T1, etc.; m = 0 - 3; and Y represents (O)jL1(CO)p(M)iQ1; j, p, i = 0 or 1; L1 = alkylene, single bond; M = O, etc.; Q1 = cyano, etc.; R = cyano, etc.] are prepared Thus, 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine was prepared in a multistep process from 2-chloro-5-bromopyrimidine and 1-tert-butoxycarbonyl-4-hydroxypiperidine. In an in vitro assay for inhibition of a histamine analog binding to the H3 receptors, compds. of this invention showed IC50 values of 0.45 nM to 1.9 nM. Processes for preparing I are disclosed. Formulations are given.


IT 832734-48-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

RN 832734-48-2 HCAPLUS

CN Benzonitrile, 4-[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:31:02 ON 27 JUN 2007)

FILE 'REGISTRY' ENTERED AT 15:32:15 ON 27 JUN 2007
ACT J115BC1/A

```

-----
L1      STR
L2 (    51529)SEA FILE=REGISTRY SSS FUL L1
L3      STR
L4 (    47061)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5      4468 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4
-----

```

FILE 'HCAPLUS' ENTERED AT 15:34:02 ON 27 JUN 2007

```

L6      406 L5
        E HISTAMINE/CT
        E E16+ALL
L7      1190 E9+OLD
        E HISTAMINE H3 ANTAGONISTS/CT
        E E3+ALL
        E E2+ALL
L8      482 E4+OLD
L9      14 L6 AND L7-8
        SEL AN 1-12 14
L10     13 E1-26 AND L9

```

FILE 'STNGUIDE' ENTERED AT 15:37:05 ON 27 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:37:59 ON 27 JUN 2007
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 15:38:08 ON 27 JUN 2007

```

L11     194 E27-220
        DEL SEL Y
L12     178 L11 AND NC5/ES

```

FILE 'HCAPLUS' ENTERED AT 15:41:32 ON 27 JUN 2007

```

L13     7 L10 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
        SEL HIT RN

```

FILE 'REGISTRY' ENTERED AT 15:42:09 ON 27 JUN 2007

```

L14     27 E1-27

```

FILE 'STNGUIDE' ENTERED AT 15:42:42 ON 27 JUN 2007

FILE 'REGISTRY' ENTERED AT 15:44:08 ON 27 JUN 2007

```

L15     8 L14 AND (C22H26N6O3 OR C21H24N4O OR C23H24F3N5O2 OR C24H28N4O2
L16     2 L15 AND (C16H22N2O OR C21H24N4O)

```

FILE 'HCAPLUS' ENTERED AT 15:49:54 ON 27 JUN 2007

```

L17     4 L16

```

FILE 'STNGUIDE' ENTERED AT 15:50:56 ON 27 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:55:55 ON 27 JUN 2007

FILE 'STNGUIDE' ENTERED AT 15:57:01 ON 27 JUN 2007

FILE 'REGISTRY' ENTERED AT 16:19:40 ON 27 JUN 2007

FILE 'HCAPLUS' ENTERED AT 16:19:47 ON 27 JUN 2007

=> => d his

(FILE 'HOME' ENTERED AT 13:23:06 ON 28 JUN 2007)

FILE 'REGISTRY' ENTERED AT 13:45:47 ON 28 JUN 2007
ACT J115BC1/A

```

-----
L1          STR
L2 (        51529)SEA FILE=REGISTRY SSS FUL L1
L3          STR
L4 (        47061)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5          4468 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4

```

```

-----
ACT J115S1/A
-----

```

```

L6          STR
L7 (        51529)SEA FILE=REGISTRY SSS FUL L6
L8          STR
L9 (        47061)SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L10 (       4468)SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 NOT L9
L11         STR
L12         491 SEA FILE=REGISTRY SUB=L10 SSS FUL L11

```

```

-----
FILE 'HCAPLUS' ENTERED AT 13:46:54 ON 28 JUN 2007

```

```

L13         52 L12
L14         40 L13 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
L15         1 US2006178375/PN
L16         1 L14 AND L15
L17         39 L14 NOT L16
          SEL HIT RN

```

```

FILE 'REGISTRY' ENTERED AT 13:48:51 ON 28 JUN 2007

```

```

FILE 'STNGUIDE' ENTERED AT 13:53:23 ON 28 JUN 2007

```

```

FILE 'REGISTRY' ENTERED AT 13:55:15 ON 28 JUN 2007
ACT J115S2/A
-----

```

```

L18         STR
L19 (        51529)SEA FILE=REGISTRY SSS FUL L18
L20         STR
L21 (        47061)SEA FILE=REGISTRY SUB=L19 SSS FUL L20
L22 (        4468)SEA FILE=REGISTRY ABB=ON  PLU=ON  L19 NOT L21
L23         STR
L24         120 SEA FILE=REGISTRY SUB=L22 SSS FUL L23

```

```

-----
ACT J115S3/A
-----

```

```

L25         STR
L26 (        51529)SEA FILE=REGISTRY SSS FUL L25
L27         STR
L28         127 SEA FILE=REGISTRY SUB=L26 SSS FUL L27

```

```

L29         618 L28,L12
L30         STR L11
L31         STR L27
L32         11 (L30 OR L31) SAM SUB=L29
L33         141 (L30 OR L31) FULL SUB=L29
          SAV TEM L33 J115S4/A
L34         477 L29 NOT L33

```

```

FILE 'HCAPLUS' ENTERED AT 13:59:11 ON 28 JUN 2007

```

```

L35         32 L34 AND L17
          DEL SEL Y
          SEL HIT RN

```

```

FILE 'REGISTRY' ENTERED AT 13:59:46 ON 28 JUN 2007

```

```

L36         318 E1-318

```

```

FILE 'STNGUIDE' ENTERED AT 14:02:21 ON 28 JUN 2007

```


COPYRIGHT (C) 2007 American Chemical Society (ACS)

DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


L6 STR



DEFAULT ECLEVEL IS LIMITED

NUMBER OF NODES IS 13

L8 STR




REP G2=(0-3) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L9 (47061)SEA FILE=REGISTRY SUB=L7 SSS FUL L8
 L10 (4468)SEA FILE=REGISTRY ABB=ON PLU=ON L7 NOT L9
 L11 . STR




REP G2=(0-3) C
 NODE ATTRIBUTES:
 NSPEC IS RC AT 14
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY AT 3
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L12 491 SEA FILE=REGISTRY SUB=L10 SSS FUL L11
 L25 STR




VAR G1=C/N
 REP G2=(0-3) C

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13


STEREO ATTRIBUTES: NONE
 L26 (51529)SEA FILE=REGISTRY SSS FUL L25
 L27 STR



REP G1=(0-1) O
 REP G2=(0-3) C
 REP G3=(0-1) AK
 REP G4=(0-1) N
 NODE ATTRIBUTES:
 NSPEC IS RC AT 18
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY AT 3
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
 L28 127 SEA FILE=REGISTRY SUB=L26 SSS FUL L27
 L29 618 SEA FILE=REGISTRY ABB=ON PLU=ON (L28 OR L12)
 L30 STR




REP G2=(0-3) C
 NODE ATTRIBUTES:
 NSPEC IS RC AT 14
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY AT 3
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L31

STR



REP G1=(0-1) O
 REP G2=(0-3) C
 REP G3=(0-1) AK
 REP G4=(0-1) N

NODE ATTRIBUTES:

NSPEC IS RC AT 18
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY AT 3
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 8
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

L33 141 SEA FILE=REGISTRY SUB=L29 SSS FUL (L30 OR L31)
 L34 477 SEA FILE=REGISTRY ABB=ON PLU=ON L29 NOT L33

=>